Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Orthopedic Surgery, Chubu Rosai Hospital, Japan Organization of Occupational Health and Safety, Nagoya, Japan.
J Clin Neurosci. 2020 Nov;81:321-327. doi: 10.1016/j.jocn.2020.09.065. Epub 2020 Oct 21.
The minimum clinically important difference (MCID) of the Japanese Orthopaedic Association (JOA) score has been reported to be around 2.5 points in cervical myelopathy. This study sought to define significant predictive factors on achieving the MCID following laminoplasty in a large series of patients with cervical spondylotic myelopathy (CSM). A total of 485 consecutive patients with CSM (295 males and 190 females; mean age: 67.0 years; age range: 42-91 years) who underwent laminoplasty were prospectively enrolled. The average postoperative follow-up period was 26.6 months (range: 12-66 months). We calculated the achieved JOA score. The relationships between outcomes and various clinical and imaging predictors including comorbidity and quantitative performance tests were examined. Logistic regression analysis was conducted to identify the predictors correlated with a JOA score of 2.5 points or more. Clinically meaningful gains were exhibited in 299 patients (61.6%) with a JOA score of ≥2.5 points, whereas 186 patients (38.4%) achieved a JOA score of <2.5 points. Univariate logistic regression analysis showed the predictive factors with a shorter duration of CSM symptoms, lower preoperative JOA scores, absence of hypertension, no use of anticoagulant/antiplatelet agents, and nonsmoking status. Multivariate logistic regression analysis determined that the duration of CSM symptoms (odds ratio: 0.771, 95% confidence interval: 0.705-0.844; p < 0.01) was the only significant predictive factor for achieving JOA scores of ≥2.5 points. An important predictor of MCID achievement following laminoplasty was shorter duration of CSM symptoms.
日本骨科协会(JOA)评分的最小临床重要差异(MCID)已报道在颈椎脊髓病中约为 2.5 分。本研究旨在通过对大量颈椎脊髓病(CSM)患者的系列研究,明确接受椎板成形术后达到 MCID 的显著预测因素。共前瞻性纳入 485 例连续的 CSM 患者(295 例男性,190 例女性;平均年龄:67.0 岁;年龄范围:42-91 岁),所有患者均接受椎板成形术。平均术后随访时间为 26.6 个月(范围:12-66 个月)。我们计算了获得的 JOA 评分。研究了结果与各种临床和影像学预测因素(包括合并症和定量性能测试)之间的关系。进行逻辑回归分析以确定与 JOA 评分≥2.5 分相关的预测因素。299 例(61.6%)患者的 JOA 评分≥2.5 分,表现出有临床意义的改善,而 186 例(38.4%)患者的 JOA 评分<2.5 分。单变量逻辑回归分析显示,具有较短的 CSM 症状持续时间、较低的术前 JOA 评分、无高血压、未使用抗凝/抗血小板药物和不吸烟状态的患者是预测因素。多变量逻辑回归分析确定,CSM 症状持续时间(优势比:0.771,95%置信区间:0.705-0.844;p<0.01)是达到 JOA 评分≥2.5 分的唯一显著预测因素。CSM 症状持续时间较短是椎板成形术后达到 MCID 的重要预测因素。